Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

By sjmartinez • June 6, 2024

Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nat Commun. 2024 Jun 5;15(1):4800. doi: 10.1038/s41467-024-48995-7. Erratum for: Nat Commun. 2024 May 8;15(1):3882. doi: 10.1038/s41467-024-48073-y. PMID: 38839763; PMCID: PMC11153605.

Tags: Dermatology, DGSOM Student, Publications

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]